Leissinger CA - Search Results

1

Prevention of bleeding in hemophilia patients with high-titer inhibitors.

Leissinger CA, Konkle BA, Antunes SV. Leissinger CA, et al. Expert Rev Hematol. 2015 Jun;8(3):375-82. doi: 10.1586/17474086.2015.1036733. Epub 2015 May 2. Expert Rev Hematol. 2015. PMID: 25937074 Review.

2

Phenotypic expressions of CCR5-delta32/delta32 homozygosity.

Nguyêñ GT, Carrington M, Beeler JA, Dean M, Aledort LM, Blatt PM, Cohen AR, DiMichele D, Eyster ME, Kessler CM, Konkle B, Leissinger C, Luban N, O'Brien SJ, Goedert JJ, O'Brien TR. Nguyêñ GT, et al. J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):75-82. doi: 10.1097/00042560-199909010-00010. J Acquir Immune Defic Syndr. 1999. PMID: 10534150

3

Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors.

Leissinger CA. Leissinger CA. Haemophilia. 1999 Sep;5 Suppl 3:25-32. doi: 10.1046/j.1365-2516.1999.00034.x. Haemophilia. 1999. PMID: 10597385 Review.

4

High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A.

Leissinger C, Becton D, Cornell C Jr, Cox Gill J. Leissinger C, et al. Haemophilia. 2001 May;7(3):258-66. doi: 10.1046/j.1365-2516.2001.00500.x. Haemophilia. 2001. PMID: 11380629 Clinical Trial.

5

Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.

Leissinger CA. Leissinger CA. Am J Hematol. 2004 Oct;77(2):187-93. doi: 10.1002/ajh.20162. Am J Hematol. 2004. PMID: 15389908 Free article. Review.

6

Inhibitor development in patients with hemophilia: an overview.

Leissinger CA. Leissinger CA. Semin Hematol. 2006 Apr;43(2 Suppl 4):S1-2. doi: 10.1053/j.seminhematol.2006.03.002. Semin Hematol. 2006. PMID: 16690370 No abstract available.

7

Prophylaxis in haemophilia patients with inhibitors.

Leissinger CA. Leissinger CA. Haemophilia. 2006 Dec;12 Suppl 6:67-72; discussion 72-3. doi: 10.1111/j.1365-2516.2006.01369.x. Haemophilia. 2006. PMID: 17123397 Review.

8

Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors.

Leissinger CA, Becton DL, Ewing NP, Valentino LA. Leissinger CA, et al. Haemophilia. 2007 May;13(3):249-55. doi: 10.1111/j.1365-2516.2007.01442.x. Haemophilia. 2007. PMID: 17498073

9

Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature.

Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Leissinger CA, et al. Am J Hematol. 2008 Feb;83(2):137-43. doi: 10.1002/ajh.21046. Am J Hematol. 2008. PMID: 17729241 Free article. Review.

10

Current management of acquired factor VIII inhibitors.

Barnett B, Kruse-Jarres R, Leissinger CA. Barnett B, et al. Among authors: leissinger ca. Curr Opin Hematol. 2008 Sep;15(5):451-5. doi: 10.1097/MOH.0b013e328309ecab. Curr Opin Hematol. 2008. PMID: 18695367 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

106 results

Search Page